Compare FirstEnergy Corp. (FE) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? FirstEnergy Corp. trades at $45.7 (market cap $26.16B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: FirstEnergy Corp. is far larger — about 26.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and FirstEnergy Corp. pays a 4.11% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold FirstEnergy Corp. for 72 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FE | MRVI | |
|---|---|---|
Market Cap | $26.16B | $972.90M |
Volume | 4,932,658 | 4,325,710 |
Sector | Utilities | Health |
52-Week High | $51.91 | $9.00 |
52-Week Low | $43.04 | $2.83 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $55.08B | $1.08B |
Dividend Yield | 4.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $45.41, up 0.11% with a bullish technical signal. The stock shows mixed earnings performance with Q1 2026 beating expectations but Q4 2025 and Q2 2026 missing. Revenue grew to $15.09B in 2025 with a 6.86% net margin. Analyst consensus is Moderate Buy with a $51.00 price target, representing 12.3% upside. Recent developments include the Energize365 investment plan and consistent dividend payments.
FirstEnergy presents a stable utility investment with moderate growth potential through infrastructure investments. Key opportunities include the $36B Energize365 plan and rising data-center demand. Risks include high debt levels ($24.03B total debt), interest rate sensitivity, and regulatory challenges. The stock offers income through dividends but faces execution risks on capital projects.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
